{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.28","value":"16.2"},{"groupId":"OG001","spread":"13.86","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.28","value":"0.2"},{"groupId":"OG001","spread":"9.38","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"Mean change from baseline in EORTC QLQ-C30 index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes","dispersionType":"Standard Deviation","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEAN","populationDescription":"The ITT analysis set included all randomized participants; \"Overall number of participants analyzed\" refers to number of participants evaluable for this outcome measure and \"Number analyzed\" refers to participants evaluable at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Cycle 6 (21 days per cycle)","title":"Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set","type":"SECONDARY","unitOfMeasure":"Score on a scale"}